These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17606721)

  • 1. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
    Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
    Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
    Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
    Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
    Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
    Simons JW; Sacks N
    Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
    Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
    Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ; Hernandez-McClain J; Henary H
    Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
    Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
    Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
    Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
    J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer.
    Dreicer R; Klein EA; Elson P; Peereboom D; Byzova T; Plow EF
    Urol Oncol; 2005; 23(2):82-6. PubMed ID: 15869991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.